Unknown

Dataset Information

0

Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies.


ABSTRACT: Peripheral T-cell lymphomas (PTCLS) comprise a diverse group of difficult to treat, very aggressive non-Hodgkin's lymphomas (NHLS) with poor prognoses and dismal patient outlook. Despite the fact that PTCLs comprise the majority of T-cell malignancies, the standard of care is poorly established. Chimeric antigen receptor (CAR) immunotherapy has shown in B-cell malignancies to be an effective curative option and this extends promise into treating T-cell malignancies. Because PTCLS frequently develop from mature T-cells, CD3 is similarly strongly and uniformly expressed in many PTCL malignancies, with expression specific to the hematological compartment thus making it an attractive target for CAR design. We engineered a robust 3rd generation anti-CD3 CAR construct (CD3CAR) into an NK cell line (NK-92). We found that CD3CAR NK-92 cells specifically and potently lysed diverse CD3+ human PTCL primary samples as well as T-cell leukemia cells lines ex vivo. Furthermore, CD3CAR NK-92 cells effectively controlled and suppressed Jurkat tumor cell growth in vivo and significantly prolonged survival. In this study, we present the CAR directed targeting of a novel target - CD3 using CAR modified NK-92 cells with an emphasis on efficacy, specificity, and potential for new therapeutic approaches that could improve the current standard of care for PTCLs.

SUBMITTER: Chen KH 

PROVIDER: S-EPMC5302909 | biostudies-other | 2016 Aug

REPOSITORIES: biostudies-other

altmetric image

Publications

Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies.

Chen Kevin H KH   Wada Masayuki M   Firor Amelia E AE   Pinz Kevin G KG   Jares Alexander A   Liu Hua H   Salman Huda H   Golightly Marc M   Lan Fengshuo F   Jiang Xun X   Ma Yupo Y  

Oncotarget 20160801 35


Peripheral T-cell lymphomas (PTCLS) comprise a diverse group of difficult to treat, very aggressive non-Hodgkin's lymphomas (NHLS) with poor prognoses and dismal patient outlook. Despite the fact that PTCLs comprise the majority of T-cell malignancies, the standard of care is poorly established. Chimeric antigen receptor (CAR) immunotherapy has shown in B-cell malignancies to be an effective curative option and this extends promise into treating T-cell malignancies. Because PTCLS frequently deve  ...[more]

Similar Datasets

| S-EPMC5629371 | biostudies-other
| S-EPMC9325690 | biostudies-literature
| S-EPMC5738277 | biostudies-literature
| S-EPMC5729624 | biostudies-literature
| S-EPMC4694800 | biostudies-other
| S-EPMC6411696 | biostudies-literature
| S-EPMC5618474 | biostudies-literature
| S-EPMC5930946 | biostudies-literature
| S-EPMC8113054 | biostudies-literature
| S-EPMC7564024 | biostudies-literature